By first targeting T-cell lymphoma, Corvus gathers crucial safety and biologic effect data in humans. This knowledge about the drug's impact on T-cells directly informs and de-risks subsequent trials in autoimmune diseases like atopic dermatitis, creating a capital-efficient development path.
Corvus Pharmaceuticals' ITK inhibitor received FDA encouragement to proceed directly from Phase 1 to a Phase 3 registrational trial for T-cell lymphoma. This was due to the disease's high mortality, lack of effective treatments, and the drug's exceptionally strong early survival data.
Corvus Pharmaceuticals is already planning frontline combination trials for its T-cell lymphoma drug. The drug's favorable safety profile is the critical enabler, allowing it to be paired with chemotherapy and used as a long-term maintenance therapy to prolong remissions—a strategy unavailable to more toxic drugs.